9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

New York Mortgage Trust, Inc. is a real estate investment trust, which engages in the acquisition, investment, finance, and management of mortgage-related single-family and multi-family residential assets. Its investment portfolio includes credit sensitive single-family and multi-family assets. The company was founded on September 26, 2003 and is headquartered in New York, NY.

RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today that the company will deliver a poster presentation highlighting vurolenatide, 9 Meters' therapeutic candidate in short bowel syndrome, and will host a booth exhibit at the in-person component of the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting, held in a hybrid format both virtually and in Las Vegas, Nevada on October 22 - 27, 2021. Participation Details: Poster Poster number: P3006 Location: Mandalay Bay Convention Center, Shoreline Exhibit Hall Presenter: Patrick H.

9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting

Ring Energy

China Rapid Finance

Looking for top penny stocks to buy? Check these 3 out for your list The post Top Penny Stocks to Watch?

Top Penny Stocks to Watch? 3 Moving in Today's Trading Session

Aikido Pharma Inc.

Progenity

Selecta Biosciences

Trevi Therapeutics Inc

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Directors. Ms. Ventimiglia currently serves as Senior Vice President, U.S. Public Affairs at Vertex Pharmaceuticals, Inc., where she is responsible for developing and overseeing the company's policy, government affairs and patient advocacy strategy, including building relationships with state and federal government officials, industry organizations, patient groups and other stakeholders.

9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors

RALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a partnership with Mend Hunger, a 501(c)(3) non-profit mobile food pantry organization that serves individuals and families in need of gluten-free food for medical and health reasons. The partnership will help Mend Hunger's Pantry Direct program to fulfill requests for gluten-free hunger relief boxes to families throughout the United States.

9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger

Dermata Therapeutics

Verastem

Zynerba Pharmaceuticals

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy The Dip According To Analysts In September

- Conference Dates: September 27th-30th - RALEIGH, NC / ACCESSWIRE / September 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below: Cantor Virtual Global Healthcare Conference  Date: Tuesday, September 28, 2021Time: 4:40 - 5:10 p.m.

9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference

Athenex

Hall of Fame Resort & Entertainment

NGL Energy Partners

Tuesday Morning Corp

Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Insiders In September

Conference Dates: September 20th-23rd RALEIGH, NC / ACCESSWIRE / September 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: September 22, 2021Time: 11:35 a.m.

9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Document Security Systems

Oragenics

Meme stocks are rallying right now, here's 3 penny stocks to watch to take advantage The post Best Penny Stocks To Buy Now? 4 Climbing As Meme Stocks Jump appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 4 Climbing As Meme Stocks Jump

- Conference Dates: September 13th-15th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference as well as participate in one-on-one meetings with investors.

9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

- Conference Dates: September 08th-10th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will be participating in Citi's 16th Annual BioPharma Virtual Conference taking place between September 8th-10th and invites investors to join virtually. Please contact your Citigroup representative to schedule a virtual one-on-one meeting with the 9 Meters management team during the Conference.

9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

CytoDyn Inc.

Jaguar Health

Biotech penny stocks are heating up right now, here's 3 for next month's watchlist The post Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month

9 Meters Biopharma Inc (NASDAQ: NMTR) has collaborated with the European Biomedical Research Institute of Salerno, Italy (EBRIS) to study larazotide for multisystem inflammatory syndrome in children (MIS-C).  Larazotide is a novel first-in-class tight junction regulator that the Company currently has in Phase 3 trial for adults with celiac disease.

9 Meters Biopharma, EBRIS Foundation Team Up For Larazotide Trial For COVID-19-Associated Complication In Children

-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence reported previously in Journal of Clinical Investigation detailing larazotide's mechanism in addressing MIS-C- RALEIGH, NC / ACCESSWIRE / August 16, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a collaboration with the European Biomedical Research Institute of Salerno, Italy (EBRIS) to study larazotide for the treatment of multisystem inflammatory syndrome in children (MIS-C). Larazotide is a novel first-in-class tight junction regulator that the Company currently has in Phase 3 clinical development for adults with celiac disease.

9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19

- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP (glucose-dependent insulinotropic polypeptide) monoclonal antibody from Lobesity - - Current capital is sufficient to fund operations into 2023 - RALEIGH, NC / ACCESSWIRE / August 12, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR) (the "Company") is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases or unique GI biology, today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021. Key Business Highlights In July, announced acquisition of humanized anti-GIP monoclonal antibody from Lobesity for the treatment of Prader-Willi Syndrome In June, announced the initiation of Phase 2 VIBRANT trial of vurolenatide for SBS In May, received USAN approval to use the designated nonproprietary name vurolenatide for its long-acting GLP-1 agonist for SBS In May, announced publication in Journal of Clinical Investigation describing successful use of larazotide for treating multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19 infection In April, announced that the Duke Clinical Research Institute will support Phase 2 VIBRANT trial in SBS In April, announced a collaboration with Celiac Disease Foundation to support clinical trial enrollment in Phase 3 study, CeDLara, for larazotide in celiac disease In April, closed a follow on offering with net proceeds of approximately $31.5 million to the Company Cash as of June 30, 2021 of $64M is expected to provide sufficient cash runway into 2023 based on the current operating plan, inclusive of the recently announced Lobesity transaction John Temperato, President & CEO of 9 Meters Biopharma, commented: "We continue to execute on our business plan and we anticipate to be able to release Phase 2 data with vurolenatide for SBS in Q4 of 2021.

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021

Conference Call Scheduled for August 12, 2021  RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Conference Call hosted by Gary Nachman and BMO Capital Markets. Please see additional details below: Biopharma Spotlight Series: Innovation in GI Conference Call  Date: Thursday, August 12th, 2021Time: 11:35 am Eastern Time Title: DEEP DIVE ON SHORT BOWEL SYNDROME  Webcast link: https://bmo.qumucloud.com/view/2021-biopharma-9meters Management: John Temperato, President & CEO Patrick Griffin , Chief Medical Officer * a replay will be available following the presentation for 90 days.

9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"

1847 GOEDEKER INC.

Intec Parent

These hot penny stocks may deserve a place on your watchlist this month The post Hot Penny Stocks to Buy Now? 4 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Now? 4 You Need to Know About

Kadmon Hlds

Performant Financial

Seelos Therapeutics

Analysts say these are penny stocks to buy. Do you agree?

7 Penny Stocks To Buy According To Analysts With Targets Up To 316%

9 Meters Biopharma Inc (NASDAQ: NMTR) has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP) from Lobesity LLC. GIP is a hormone whose concentration increases significantly with overeating, leading to higher glucose absorption and greater insulin release.

9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders

- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling studies ongoing with first-in-human studies anticipated in 2023 - - Transaction does not impact corporate guidance and company remains fully financed into 2023 with co-lead programs' in short bowel syndrome (Phase 2) and in celiac disease (Phase 3) - RALEIGH, NC / ACCESSWIRE / July 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company has acquired global development rights to a proprietary and highly specific humanized monoclonal antibody (mAb), LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP), in addition to related intellectual property from Lobesity LLC, a privately-held biotechnology company focused on breakthrough research and development for metabolic diseases and related disorders. GIP is a hormone found in the upper small intestine that is released into the blood after food is ingested.

9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity

Akebia Therapeutics

Borqs Technologies

Which penny stocks are the best for your watchlist in 2021? The post Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.

Implied Volatility Surging for 9 Meters Biopharma (NMTR) Stock Options

Arcos Dorados Hlds

Axcella Health Inc

Lantronix

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will participate in a virtual fireside chat at the William Blair Biotech Focus Conference being held July 14-15, 2021 and invites investors to join live via webcast. William Blair Biotech Focus Conference Date: July 15th, 2021Time: 2:00 to 2:45 p.m.

News for 9 Meters Biopharma Stock (NMTR)